Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$7.87
-0.44 (-5.29%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $34.8M · quality 45.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
14/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.2B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-17.5%
↓Gross Margin
31.5%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-41.2%
FCF CAGR
—
FCF margin
24.5%
FCF / Net income
-0.25x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $141.9M · net income $-136.9M · FCF $34.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $141.9M | $141.9M | $251.7M | $655.4M | $698.8M |
| Net Income | $-136.9M | $-136.9M | $-346.5M | $-21.3M | $-77.5M |
| EBITDA | $-93.2M | $-93.2M | $-333.1M | $31.4M | $-2.5M |
| EPS | -0.50 | -0.50 | -1.26 | -0.08 | -0.40 |
| Gross Margin | 31.5% | 31.5% | 52.5% | 83.3% | 85.8% |
| Operating Margin | -55.1% | -55.1% | -30.5% | 6.4% | 9.2% |
| Net Margin | -96.5% | -96.5% | -137.7% | -3.2% | -11.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.23 | 0.25 | 0.41 |
| Cash Flow | |||||
| Free Cash Flow | $34.8M | $34.8M | $-57.0M | $183.7M | $-201.1M |
| Returns | |||||
| ROE | -17.5% | -17.5% | -37.0% | -1.6% | -5.9% |
| Valuation | |||||
| EV/EBITDA | — | — | — | 70.55 | — |
| P/B | 2.76 | 2.76 | 1.84 | 1.98 | 1.68 |
| Growth & Yield | |||||
| Revenue Growth | -43.6% | -43.6% | -61.6% | -6.2% | — |
| EPS Growth | 60.5% | 60.5% | -1529.4% | 80.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+16.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.26 → -0.50
Residual
+16.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.